Influence of provider characteristics and insurance status on maternal serum alpha-fetoprotein screening

Journal of the American Board of Family Practice

Volumn 11, Issue 5, 1998, Pages 357-365

  Jenkins Woelk, Laura D ^a   Baldwin, Laura Mae ^b   Raine, Tina R ^c   Hart, Gary L ^b   Fordyce, Meredith A ^b   Rosenblatt, Roger A ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ARTICLE; BLOOD; CLINICAL PRACTICE; ECONOMICS; FEMALE; HEALTH INSURANCE; HUMAN; MALE; MASS SCREENING; MEDICAID; MIDDLE AGED; NEURAL TUBE DEFECT; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ALPHA-FETOPROTEINS; FEMALE; HUMANS; INSURANCE, PHYSICIAN SERVICES; MALE; MASS SCREENING; MEDICAID; MIDDLE AGED; NEURAL TUBE DEFECTS; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; RETROSPECTIVE STUDIES; UNITED STATES; WASHINGTON;

EID: 0032161512     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: 10.3122/15572625-11-5-357     Document Type: Article

References (39)

1. Haddow JE, Macri JN. Commentary: prenatal screening for neural tube defects.JAMA 1979;242:515-6.
2. Chavez GF, Cordero JF, Becerra JE. Leading major congenital malformations among minority groups in the, United States 1981-1986. MMWR CDC Surveill Summ 1988;37(3):17-24.
3. Althouse R, Wald N. Survival and handicap of infants with spina bifida. Arch Dis Child 1980;55:845-50.
4. Main DM, Mennuti MT. Neural tube defects: issues in prenatal diagnosis and counselling. Obstet Gynecol 1986;67:1-16.
5. American College of Obstetricians and Gynecologists. Alpha-fetoprotein. AGOG technical bulletin 154. Washington, DC: AGOG, 1991.
6. Ward NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977;1:1323-32.
7. Macri JN, Haddow JE, Weiss RR. Screening for neural tube defects in the United States. A summary of the Scarborough Conference. Am J Obstet Gynecol 1979;133:119-25.
8. Milunsky A, Alpert E, Neff RK, Frigoletto FD Jr. Prenatal diagnosis of neural tube defects. IV. Maternal serum alpha-fetoprotein screening. Obstet Gynecol 1980;55:60-6.
9. Burton BK, Sowers SG, Nelson LH. Maternal serum alpha-fetoprotein screening in North Carolina: experience with more than twelve thousand pregnancies. Am J Obstet Gynecol 1983;146:439-44.
10. Cowan LS, Phelps-Sandall B, Hanson FW, Peterson AG, Tennant FR. A prenatal diagnostic center's first year experience with the California alpha-Fetoprotein Screening Program. Am J Obstet Gynecol 1989;160:1496-504.
11. Layde PM, von Allmen SD, Oakley GP Jr. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis. Am J Public Health 1979;69:566-73.
12. Annas GJ. Is a genetic screening test ready when the lawyers say it is? Hastings Cent Rep 1985;15:16-8.
13. Milunsky A, Haddow JE. Cautions about maternal serum alpha-fetoprotein screening. N Engl J Med 1985;313:694.
14. American Society of Human Genetics. Policy statement for maternal alpha-fetoprotein screening programs and quality control for laboratories performing maternal serum alpha-fetoprotein amniotic fluid and alpha-fetoprotein assays. Am J Hum Genet 1987;40:75-82.
15. American Academy of Pediatrics: Committee on Fetus and Newborn; and American College of Obstetricians and Gynecologists: Committee on Obstetrics: Maternal and Fetal Medicine. Guidelines for perinatal care. 3rd ed. Elk Grove Village, 111: American Academy of Pediatrics; Washington, DC: American College of Obstetricians and Gynecologists, 1992.
16. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
17. Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992;80(3 Pt 1):353-8.
18. Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1993;81:72-7.
19. Madlon-Kay DJ, Reif C, Mersy DJ, Luxenberg MG. Maternal serum alpha-fetoprotein testing: physician experience and attitudes and their influence on patient acceptance. J Fam Pract 1992;35:395-400.
20. Baldwin LM, Raine T, Jenkins LD, Hart LG, Rosenblatt RA. Do providers adhere to ACOG standards? The case of prenatal care. Obstet Gynecol 1994;84:549-56.
21. Shah BV, Folsom RE, LaVange LM, Whelless SC, Boyle KE, Williams RL. Statistical methods and mathematical algorithms used in SUDAAN. Research Triangle Park, NC: Research Triangle Institute, 1993.
22. Burton BK. Maternal serum alpha-fetoprotein screening. Pediatr Ann 1989;18:687-92, 694-7.
23. Sokal DC, Byrd JR, Chen AT, Goldberg MF, Oakley GP Jr. Prenatal chromosomal diagnosis: racial and geographic variation for older women in Georgia. JAMA 1980;244:1355-7.
24. Halliday J, Lumley J, Watson L. Comparison of women who do and do not have amniocentesis or chorionic villus sampling. Lancet 1995;345:704-9.
25. Taplin SH, Thompson RS, Conrad DA. Cost-justification analysis of prenatal maternal serum alpha-feto protein screening. Med Care 1988;26:1185-202.
26. Dobie S, Hart LG, Fordyce M, Andrilla CHA, Rosenblatt RA. Obstetric care and payment source: do low-risk Medicaid women get less care? Am J Public Health, 1998;88:51-6.
27. Ayanian JZ, Udvarhelyi IS, Gatsonis CA, Pashos CL, Epstein AM. Racial differences in the use of revascularization procedures after coronary angiography. JAMA 1993;269:2642-6.
28. Greenberg ER, Chute CG, Stukel T, Baron JA, Freeman DH, Yates J, et al. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med 1988;318:612-7.
29. Wenneker MB, Weissman JS, Epstein AM. The association of payer with utilization of cardiac procedures in Massachusetts. JAMA 1990;264:1255-60.
30. Braveman PA, Egerter S, Bennett T, Showstack J. Differences in hospital resource allocation among sick newborns according to insurance coverage. JAMA 1991;266:3300-8.
31. Kogan MD, Kotelchuck M, Alexander GR, Johnson WE. Racial disparities in reported prenatal care advice from health care providers. Am J Public Health 1994;84:82-8.
32. Wash Rev Code §70.54.220 (1988).
33. Nadel AS, Green JK, Holmes LB, Frigoletto FD Jr, Benacerraf BR. Absence of need for amniocentesis in patients with elevated levels of MSAFP and normal ultrasonographic examinations. N Engl J Med 1990;323:557-61.
34. Richards DS, Seeds JW, Katz VL, Lingley LH, Albright SG, Cefalo RC. Elevated maternal serum alpha-fetoprotein with normal ultrasound: is amniocentesis always appropriate? A review of 26,069 screened patients. Obstet Gynecol 1988;71:203-7.
35. Statham H, Green J. Serum screening for Down's syndrome: some women's experiences. BMJ 1993;307:174-6.
36. Salonen R, Kurki L, Lappalainen M. Experiences of mothers participating in maternal serum screening for Down's syndrome. Eur J Hum Genet 1996;4:113-9.
37. Khalid L, Price SM, Barrow M. The attitudes of midwives to maternal serum screening for Down's syndrome. Public Health 1994;108:131-6.
38. Green JM. Serum screening for Down's syndrome: experiences of obstetricians in England and Wales. BMJ 1994;309:769-72.
39. Sadler M. Serum screening for Down's syndrome: how much do health professionals know? Br J Obstet Gynaecol 1997;104:176-9.